X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PIRAMAL ENTERPRISES - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PIRAMAL ENTERPRISES DR. REDDYS LAB/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 29.9 36.6 81.8% View Chart
P/BV x 2.9 3.0 96.4% View Chart
Dividend Yield % 0.9 0.8 115.1%  

Financials

 DR. REDDYS LAB   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
PIRAMAL ENTERPRISES
Mar-17
DR. REDDYS LAB/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3,3972,095 162.1%   
Low Rs2,5601,025 249.8%   
Sales per share (Unadj.) Rs856.5492.8 173.8%  
Earnings per share (Unadj.) Rs78.072.6 107.4%  
Cash flow per share (Unadj.) Rs139.994.7 147.8%  
Dividends per share (Unadj.) Rs20.0021.00 95.2%  
Dividend yield (eoy) %0.71.3 49.9%  
Book value per share (Unadj.) Rs739.8862.5 85.8%  
Shares outstanding (eoy) m165.74172.56 96.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.53.2 109.8%   
Avg P/E ratio x38.221.5 177.7%  
P/CF ratio (eoy) x21.316.5 129.2%  
Price / Book Value ratio x4.01.8 222.6%  
Dividend payout %25.728.9 88.6%   
Avg Mkt Cap Rs m493,632269,194 183.4%   
No. of employees `00022.74.0 565.2%   
Total wages/salary Rs m31,06817,939 173.2%   
Avg. sales/employee Rs Th6,259.021,190.3 29.5%   
Avg. wages/employee Rs Th1,369.84,470.1 30.6%   
Avg. net profit/employee Rs Th569.73,120.0 18.3%   
INCOME DATA
Net Sales Rs m141,96185,037 166.9%  
Other income Rs m1,7152,338 73.4%   
Total revenues Rs m143,67687,374 164.4%   
Gross profit Rs m24,72234,991 70.7%  
Depreciation Rs m10,2663,817 269.0%   
Interest Rs m63420,310 3.1%   
Profit before tax Rs m15,53713,202 117.7%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m2,9652,281 130.0%   
Profit after tax Rs m12,92112,520 103.2%  
Gross profit margin %17.441.1 42.3%  
Effective tax rate %19.117.3 110.4%   
Net profit margin %9.114.7 61.8%  
BALANCE SHEET DATA
Current assets Rs m96,83787,590 110.6%   
Current liabilities Rs m84,199185,578 45.4%   
Net working cap to sales %8.9-115.2 -7.7%  
Current ratio x1.20.5 243.7%  
Inventory Days Days7331 236.3%  
Debtors Days Days9848 205.4%  
Net fixed assets Rs m102,552108,523 94.5%   
Share capital Rs m829345 240.2%   
"Free" reserves Rs m121,792148,481 82.0%   
Net worth Rs m122,621148,826 82.4%   
Long term debt Rs m5,449144,957 3.8%   
Total assets Rs m218,165482,394 45.2%  
Interest coverage x25.51.7 1,545.8%   
Debt to equity ratio x01.0 4.6%  
Sales to assets ratio x0.70.2 369.1%   
Return on assets %6.26.8 91.3%  
Return on equity %10.58.4 125.3%  
Return on capital %12.912.0 107.9%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67015,001 544.4%   
Fx outflow Rs m26,3555,150 511.8%   
Net fx Rs m55,3159,851 561.5%   
CASH FLOW
From Operations Rs m21,444-100,393 -21.4%  
From Investments Rs m-18,404-24,202 76.0%  
From Financial Activity Rs m-3,692135,705 -2.7%  
Net Cashflow Rs m-1,14411,110 -10.3%  

Share Holding

Indian Promoters % 25.5 52.9 48.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.0 135.0%  
FIIs % 35.3 26.6 132.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 16.5 92.7%  
Shareholders   75,885 93,274 81.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFE  STERLING BIOTECH  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS